RAPT Therapeutics, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- RAPT Therapeutics, Inc. (Nasdaq: RAPT) is a clinical-stage immunology-based biopharmaceutical company that discovers, develops and commercializes oral small-molecule therapies modulating critical immune responses for patients with significant unmet needs in inflammatory diseases. The company focuses on targeting chemokine receptors such as CCR4 to inhibit migration of inflammatory immune cells including type 2 T helper cells; its lead candidate zelnecirnon (RPT193), an oral CCR4 antagonist, targets atopic dermatitis and asthma though its Phase 2 trial for atopic dermatitis faced an FDA clinical hold in early 2024; it has advanced ozureprubart (RPT904) into the prestIgE Phase 2b clinical trial for food allergies initiated in October 2025; earlier pipeline assets include tivumecirnon (FLX475) for oncology applications selectively inhibiting regulatory T cell migration into tumors, alongside discovery-stage programs targeting GCN2 and HPK1. RAPT Therapeutics, founded in 2015 as FLX Bio, Inc. and rebranded in 2018 before its 2019 Nasdaq IPO, maintains headquarters in South San Francisco, California, and operates primarily in the United States with a global focus on immunology research and clinical development. Recent developments include a $150 million private placement financing in December 2024 led by The Column Group and TCGX with participation from investors such as BVF Partners LP, Deep Track Capital, Foresite Capital, Medicxi, OrbiMed, Perceptive Advisors, Redmile Group and RTW Investments to fund its inflammatory disease pipeline; and reporting third quarter 2025 financial results in November 2025 alongside plans to disclose topline data from partner Jeyou's Phase 2 trial of ozureprubart in asthma.
This Biotech Was Quietly Bought Before a $58 Per Share Takeout
This Investor Built a $56 Million Position in RAPT Last Quarter. It Was Just Acquired for $58 Per Share
This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges
Halper Sadeh LLC is Investigating Whether RAPT, CTGO, TBN, FOLD are Obtaining Fair Deals for their Shareholders
Contrasting Solid Biosciences (NASDAQ:SLDB) & Rapt Therapeutics (NASDAQ:RAPT)
Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders?
Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC is Investigating Whether NWE, DHIL, RAPT are Obtaining Fair Prices for its Shareholders
RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPT
Halper Sadeh LLC Reminds Shareholders of RAPT, PEN, CVGW, FONR of the Firm’s Investigations
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RAPT Therapeutics, Inc. (Nasdaq – RAPT), Penumbra, Inc. (NYSE – PEN), Calavo Growers, Inc. (Nasdaq – CVGW), FONAR Corporation (Nasdaq - FONR)
Rapt Therapeutics (NASDAQ:RAPT) Reaches New 52-Week High – Should You Buy?
Halper Sadeh LLC Encourages PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC Encourages PEN and RAPT Shareholders to Contact the Firm to Discuss Their Rights
RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPT
GSK to Boost Respiratory & Immunology Pipeline With $2.2B RAPT Buyout
S&P 500 Records Worst Session Since October: Investor Sentiment Dips, Fear & Greed Index In 'Neutral' Zone
Halper Sadeh LLC Encourages CVGW, RAPT, CFLT Shareholders to Contact the Firm to Discuss Their Rights
Why Rapt Therapeutics Stock Soared Today
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RAPT Therapeutics, Inc. (Nasdaq – RAPT), Penumbra, Inc. (NYSE – PEN), Calavo Growers, Inc. (Nasdaq – CVGW), FONAR Corporation (Nasdaq - FONR)